Management of Histamine-Related Disorders

Introduction

• Histamine-related disorders require comprehensive management, including pharmacological and non-pharmacological interventions, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 2

Pharmacological Interventions

• The American Academy of Allergy, Asthma, and Immunology recommends using H2 receptor antagonists, such as ranitidine or famotidine, in combination with H1 blockers for comprehensive histamine control 1
• H2 receptor antagonists are particularly effective for gastrointestinal symptoms related to histamine excess, including diarrhea, abdominal pain, nausea, and vomiting 3
• Mast cell stabilizers, such as oral cromolyn sodium, can help control histamine-related symptoms, including gastrointestinal and neuropsychiatric manifestations 3, 1
• Leukotriene receptor antagonists, such as montelukast, may reduce symptoms, particularly if urinary LTE4 levels are increased, and are most effective for respiratory symptoms 1
• Omalizumab, an anti-IgE therapy, can reduce mast cell activation and is effective for preventing anaphylactic episodes in patients with mast cell activation disorders 1
• Initial treatment with standard dose of second-generation H1 antihistamines, such as cetirizine 10 mg/day, loratadine 10 mg/day, fexofenadine 180 mg/day, and desloratadine 5 mg/day, with the option to increase the dose up to 4 times the standard dose if symptoms persist, as recommended by the American Academy of Allergy, Asthma, and Immunology 4, 5
• Consider omalizumab for chronic spontaneous urticaria (CSU) at a recommended dosing of 300mg subcutaneously every 4 weeks, with approximately 65-87% of patients responding to therapy, as recommended by the American Academy of Allergy, Asthma, and Immunology 5
• Cyclosporine can be used for refractory cases at a dosage of up to 5mg/kg body weight, requiring monitoring of blood pressure and renal function every 6 weeks, as recommended by the American Academy of Allergy, Asthma, and Immunology 5
• The following treatment steps are recommended:

Non-Pharmacological Interventions

• Avoidance of histamine triggers, such as temperature extremes, mechanical irritation, alcohol, and certain medications, can help reduce histamine-related symptoms 1
• Continuous warm-up before exercise can reduce histamine-related bronchoconstriction 6
• Premedication with antihistamines, such as non-sedating antihistamine loratadine, taken 2 hours before injections, can reduce both the number and severity of systemic reactions during allergen immunotherapy 7

Safety Considerations

• First-generation antihistamines should be avoided for long-term use due to sedation, impaired driving ability, cognitive decline, particularly in elderly patients 1
• For patients anticipating allergen exposure, premedication should begin 1 day before exposure and continue for 5 days total, according to the American Academy of Allergy, Asthma, and Immunology 2
• The American Academy of Allergy, Asthma, and Immunology recommends considering a non-cross-reactive contrast agent from a different group for patients with a history of severe delayed reactions to contrast media 2
• Avoid prolonged use of corticosteroids due to their adverse effects, and reserve them for acute exacerbations in short courses (3-10 days), as recommended by the American College of Allergy, Asthma, and Immunology 4
• If necessary, prednisone can be used at a dose of 0.5-1 mg/kg/day until symptoms resolve to grade 1, as recommended by the American College of Allergy, Asthma, and Immunology 4

Diagnosis and Monitoring

• Chronic urticaria is associated with thyroid autoimmunity, with thyroid autoantibodies present in approximately 14-36% of patients compared to 6% in the general population 8, 5
• The 2022 international urticaria guidelines recommend measuring IgG anti-thyroid peroxidase (anti-TPO) levels as part of the basic diagnostic workup for chronic spontaneous urticaria (CSU) 5
• Include thyroid autoantibodies (anti-TPO) and thyroid function tests in the diagnostic workup, particularly for patients with more severe disease not responding to H1 antihistamines 8, 5
• Validated tools, such as the 7-Day Urticaria Activity Score (UAS7) and the Urticaria Control Test (UCT), should be used to monitor disease activity and treatment response, as recommended by the Journal of Allergy and Clinical Immunology 5
• Evaluate response to treatment after 2 weeks before modifying therapy, using validated tools such as the Urticaria Control Test (UCT) and the Urticaria Activity Score (UAS7) to monitor disease control, as recommended by the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma, and Immunology 4, 5

Anaphylaxis Management

• If urticaria is accompanied by signs of anaphylaxis, epinephrine is the first-line treatment, followed by combined H1+H2 blockade, and emergency care should be sought immediately, as recommended by the Journal of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma, and Immunology 9, 10, 2
• Epinephrine 0.3 mg IM in the mid-antrolateral thigh is recommended as first-line treatment for patients with angioedema or signs of anaphylaxis, and seeking immediate emergency medical attention, as recommended by the Journal of Allergy and Clinical Immunology 2
• After epinephrine administration, combined H1+H2 blockade is recommended for anaphylaxis management, typically with diphenhydramine (1-2 mg/kg or 25-50 mg IV) plus ranitidine (50 mg IV), as recommended by the Journal of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma, and Immunology 11, 12, 2

Special Considerations

• Pediatric patients should start with age-appropriate dosing of second-generation H1-antihistamines, with medication dosing must be weight-based, and patients with anaphylaxis risk should be educated regarding signs, symptoms, and treatment of anaphylaxis, with prescription of epinephrine autoinjector if appropriate, as recommended by the American Academy of Allergy, Asthma, and Immunology and the American Academy of Pediatrics 5, 13
• Food allergies are a common cause of urticaria in infants and may require evaluation by an allergist, as recommended by the American Academy of Pediatrics 13